Where Teva failed, Eli Lilly gained — migraine drug Emgality wins US approval for episodic cluster headaches
It may be trailing behind its rivals in migraine sales, but Lilly’s Emgality has secured the FDA nod for episodic cluster headaches.
Emgality was …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
